ClinicalTrials.gg
CompletedNCT01167101Updated Sep 4, 2015

Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

An interventional study of Rebamipide and pantoprazole in Stomach Ulcer, sponsored by Kangdong Sacred Heart Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-09-04.

Sponsored by Kangdong Sacred Heart Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Stomach Ulcer with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Stomach Ulcer · Korea, Republic of.

Enrollment
7th of 17
290 · median 199
Started
2009
the only one that year
No phase
Only one
of the 20
Registered
4th of 20
by date

Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2009, is the only one with no phase, and was the 4th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

2 of the 20 studies in Stomach Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stomach Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (PPI) on post ESD ulcer healing.

03

Conditions studied

  • Stomach Ulcer

Browse trials for

Keywords

  • Rebamipide
  • gastric ulcer
  • healing rate
  • iatrogenic gastric ulcer after endoscopic submucosal dissection
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients underwent ESD for gastric adenoma or cancer

Exclusion criteria

Exclusion Criteria:

  • subjects with previous gastric surgery
  • subjects taking aspirin, anticoagulant, or antiplatelet agent
  • subjects having except gastric cancer
  • pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
290 participants (actual)

Study arms

  • Other
    Pantoprazole

    controls Pantoprazole 40mg qd for 28days

    Drug: pantoprazole

  • Active comparator
    Pantoprazole + Rebamipde

    Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days

    Drug: Rebamipide · Drug: pantoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Healing efficacy of Rebamipide in the treatment of iatrogenic gastric ulcer

    Healing efficacy will be assessed by the change of ulcer size. Quality of Ulcer Healing(QOUH) wil be assessed by nodularity in the healed ulcer by two endoscopist.

    Time frame: at 2month after endoscopic submucosal dissection (ESD)

07

Study locations

1 site
  • Kangdong Sacred Heart Hospital
    Seoul, 134-701, Korea, Republic of
08

References and documents

Publications

  • Shin WG, Kim SJ, Choi MH, Kim KO, Jang HJ, Park CH, Baek IH, Kim KH, Baik GH, Kae SH, Kim JH, Kim HY. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc. 2012 Apr;75(4):739-47. doi: 10.1016/j.gie.2011.11.004. Epub 2012 Jan 26. PubMed 22281110 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2010
First posted
Jul 22, 2010
Start
May 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Last update
Sep 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01167101
Lead sponsor
Kangdong Sacred Heart Hospital
Responsible party
Shin, Woon Geon (Professor, Kangdong Sacred Heart Hospital) — Principal investigator
First posted
Jul 22, 2010
Start date
May 2009
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Sep 4, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rebamipide

Start the discussion